Supreme Court rules that "pay for delay" agreement restrains trade

06/18/2013

Yesterday the U.S. Supreme Court announced a 5-3 decision in FTC v. Actavis which ends the legal presumption that “pay for delay” agreements among branded and generic drug companies are legal. The decision will allow the FTC to challenge and block these agreements when it finds them to reduce competition from other generic drug companies. “While not unexpected, this decision effectively will shorten the patent protection period for many drugs, shortening the time a company can recoup its development costs,” said Coalition for Healthcare Communication Executive Director John Kamp. Read more.
Catch additional coverage of the decision from The Wall Street Journal, Reuters and CNBC.

View Full Article in:

http://www.cohealthcom.org/2013/06/18/update-supreme-court-decision-ends-presump...

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX